Stelara biosimilars comparison

Biosimilars

Compare Stelara (ustekinumab) biosimilars to the reference product. Stelara biosimilars offer the same efficacy for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis at potentially lower cost. Multiple biosimilars are now FDA-approved.

Select any two to compare side by side

All products in this comparison

ProductManufacturerRouteFrequencyKey difference
Stelara (reference)JanssenSC injection / IV infusionEvery 8–12 weeks (SC); single IV induction for IBDOriginal reference product; extensive long-term safety data
Wezlana (ustekinumab-auub)AmgenSC injection / IV infusionSame as referenceFirst FDA-approved Stelara biosimilar; interchangeable
Pyzchiva (ustekinumab-ttwe)Samsung BioepisSC injection / IV infusionSame as referenceFDA-approved biosimilar; interchangeable designation
Otulfi (ustekinumab-arhi)Fresenius KabiSC injection / IV infusionSame as referenceFDA-approved biosimilar
Imuldosa (ustekinumab-aekn)CelltrionSC injection / IV infusionSame as referenceFDA-approved biosimilar
Selarsdi (ustekinumab-sbir)SandozSC injection / IV infusionSame as referenceFDA-approved biosimilar from Sandoz
Pyzchiva (ustekinumab-ttwe): 2nd entryBioconSC injection / IV infusionSame as referenceAdditional manufacturer for expanded supply

Related guides

Denied one of these medications?

Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.